Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.

[1]  M. Kohli,et al.  Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma. , 2015 .

[2]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[3]  M. Millward,et al.  A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. , 2013, Clinical genitourinary cancer.

[4]  A. Eisen,et al.  Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. , 2013, The Lancet. Oncology.

[5]  G. Pond,et al.  Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. , 2013, European urology.

[6]  E. Plimack,et al.  Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  L. Schwartz,et al.  Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. , 2012, The Lancet. Oncology.

[8]  P. Kantoff,et al.  Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Suzanne F. Jones,et al.  Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. , 2010, The oncologist.

[10]  D. Gandara,et al.  Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. , 2010, Urology.

[11]  S. Sleijfer,et al.  (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. , 2010, The oncologist.

[12]  S. Culine,et al.  Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Milowsky,et al.  Phase II study of sunitinib in patients with metastatic urothelial cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Tangen,et al.  Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium , 2010, BJU international.

[15]  S. Culine,et al.  Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Wilding,et al.  Phase 2 trial of sorafenib in patients with advanced urothelial cancer , 2009, Cancer.

[17]  David C. Smith,et al.  Vinflunine in platinum‐pretreated patients with locally advanced or metastatic urothelial carcinoma , 2009, Cancer.

[18]  J. Machiels,et al.  A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma , 2009, Cancer.

[19]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[20]  David C. Smith,et al.  Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Obasaju,et al.  Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Culine,et al.  A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen , 2006, British Journal of Cancer.

[23]  Sergio Ricci,et al.  Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Weicheng Wu,et al.  VEGF receptor expression and signaling in human bladder tumors , 2003, Oncogene.

[25]  R. Millikan,et al.  Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Gutheil,et al.  Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  P. Albers,et al.  Gemcitabine Monotherapy as Second-Line Treatment in Cisplatin-Refractory Transitional Cell Carcinoma – Prognostic Factors for Response and Improvement of Quality of Life , 2002, Oncology Research and Treatment.

[28]  C. Sternberg,et al.  Chemotherapy with an every‐2‐week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin‐based therapy , 2001, Cancer.

[29]  M. Dimopoulos,et al.  Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  J. Hainsworth,et al.  Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Krege,et al.  Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. , 2001, The Journal of urology.

[32]  P. Albers,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  C. Sweeney,et al.  A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium , 1999, Cancer.

[34]  G. Luporini,et al.  A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum , 1998 .

[35]  G. Luporini,et al.  A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. , 1998, European journal of cancer.

[36]  M. Mazumdar,et al.  Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. Groshen,et al.  Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. , 1995, Journal of the National Cancer Institute.

[38]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.